HomeBusiness NewsCAR T-Cell Therapy Market Trends, Analysis & Forecast 2034

CAR T-Cell Therapy Market Trends, Analysis & Forecast 2034

I am nainad (nainadeshmukh777@gmail.com). I hold full responsibility for this content, which includes text, images, links, and files. The website administrator and team cannot be held accountable for this content. If there is anything you need to discuss, you can reach out to me via nainadeshmukh777@gmail.com email.

The CAR T-cell treatment market is expected to grow at a compound annual growth rate (CAGR) of 17.7% during the following ten years, from 2024 to 2034, from its estimated value of US$ 2.25 billion in 2024 to US$ 11.49 billion by the end of 2034.

Increased leukemia incidence, a surge in research and development to generate novel CAR T-cell therapy, and CAR T-cell therapy’s better efficacy over other conventional cancer treatments are the main factors driving the market growth for CAR T-cell therapy.

Get Free Sample Copy of This Report:

CAR T-cell therapy is a breakthrough approach in the field of cancer treatment. This method of immunotherapy uses the patient’s own cells to attack cancer. The remarkable success of CAR T-cell therapy in treating several hematologic malignancies, including certain forms of leukemia and lymphoma, has highlighted the treatment’s potential as a game-changing option for patients who have not responded to conventional treatments.

Key Takeaways from Market Study

  • It is projected that the CAR T-cell treatment market will be worth US$ 2.25 billion by 2024.
  • From 2024 to 2034, the demand for Car T-cell treatment is expected to grow at a CAGR of 17.7%.
  • The market is expected to reach US$ 11.49 billion by the end of 2034.
  • In 2024, North America is projected to hold a 65.7% market share.
  • From 2024 to 2034, the demand for Yescarta (axicabtagene ciloleucel) is anticipated to grow at a CAGR of 17.4%.
  • Through 2034, the North American market is expected to grow at a CAGR of 16.5%.
  • The Western European market is expected to grow at a CAGR of 18.7% between 2024 and 2034.

“Chimeric antigen receptor-expressing (CAR) T-cells are engineered from donors or patients to express a specific tumor antigen. Increased research and development in CAR T-cell therapy, along with an increase in cancer incidence, are expected to have an impact on market growth until 2034. A Fact.MR analyst states, “CAR T-cell therapies hold great promise as a novel approach to cancer treatment that harnesses the immune system to combat illness.”

Key Companies Profiled in This Report

  • Autolus Therapeutics
  • 2Seventy Bio, Inc.
  • Bristol-Myers Squibb
  • Pfizer
  • Gilead Sciences
  • Intellia Therapeutics
  • Caribou Biosciences, Inc.
  • Cartesian Therapeutics, Inc.
  • Novartis AG

Rising Leukemia Cases Worldwide Fueling Demand for CAR T-Cell Therapy

The market for CAR T-cell treatment is being driven in part by the increasing incidence of leukemia. Leukemia is characterized by the uncontrolled proliferation of abnormal white blood cells, and cases of this disease have increased recently.

  • According to the American Cancer Society, there were roughly 60,650 new cases of leukemia discovered in the US in 2022.

This increase may have multiple causes, such as alterations in lifestyle, environmental exposures, and genetic predispositions. CAR T-cell therapy is one cutting-edge immunotherapy that has grown in favor as a potential leukemia treatment. This therapy approach enhances cancer cell identification and elimination by changing the patient’s own T cells.

Get Customization on this Report for Specific Research Solutions:

More Valuable Insights on Offer

True, With its latest product, MR offers a dispassionate evaluation of the CAR T-cell treatment business covering the years 2018 through 2023 as well as projections for 2024 through 2034.

In six major regions of the world—North America, Latin America, Europe, East Asia, South Asia & Oceania, and MEA—the study provides crucial insights into the market based on product (Yescarta [axicabtagene ciloleucel], Kymriah [tisagenlecleucel], JCAR017 [lisocabtagene maraleucel], bb2121), indication (relapsed large B-cell lymphoma, acute lymphoblastic leukemia [ALL], multiple myeloma), and end user (hospitals, cancer treatment centers).


US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com